CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
The company had incurred an adjusted loss of 24 cents in the year-ago quarter. Total revenues, the majority of which comprised product revenues, amounted to $128.7 million in the reported quarter, representing growth of 25.3% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $123 million. Catalyst's top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and epilepsy drug, Fycompa (perampanel) CIII. Revenues generated from the sale of the newly launched muscle disease drug, Agamree (vamorolone), also contributed to the top line. The stock gained 7% in the after-market hours on Nov. 6 as the investors were impressed by the better-than-expected third-quarter results. See the Zacks Earnings Calendar to stay ahead of market-making news. Firdapse generated sales worth $79.3 million in the reported quarter, up 19.7% year over year. The reported figure bea
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to WorkGlobeNewswire
- Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at Truist Financial Co. from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
CPRX
Earnings
- 11/6/24 - Beat
CPRX
Sec Filings
- 11/15/24 - Form 4
- 11/14/24 - Form 144
- 11/14/24 - Form SC
- CPRX's page on the SEC website